Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the children's oncology group

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 633-638

  Meyers, Paul A ^a   Schwartz, Cindy L ^a   Krailo, Mark D ^a   Healey, John H ^a   Bernstein, Mark L ^a   Betcher, Donna ^a   Ferguson, William S ^a   Gebhardt, Mark C ^a   Goorin, Allen M ^a   Harris, Michael ^a   Kleinerman, Eugenie ^a   Link, Michael P ^a   Nadel, Helen ^a   Nieder, Michael ^a   Siegal, Gene P ^a   Weiner, Michael A ^a   Wells, Robert J ^a   Womer, Richard B ^a   Grier, Holcombe E ^a  

^a CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; MURAMYL TRIPEPTIDE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; BONE TUMOR; COMPARATIVE STUDY; INFANT; LUNG TUMOR; MORTALITY; PRESCHOOL CHILD; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; INFANT; LUNG NEOPLASMS; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; SURVIVAL RATE;

EID: 39149136228     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.14.0095     Document Type: Article

References (19)

1. Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am 44:973-989, 1997
2. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986
3. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 10:5-15, 1992
4. Link M, Meyers PA, Gebhardt M: Osteosarcoma, in Pizzo P, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2006, pp 1074-1115
5. Harris MB, Cantor AB, Goorin AM, et al: Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated - A Pediatric Oncology Group study. Med Pediatr Oncol 24:87-92, 1995
6. Kung FH, Pratt CB, Vega RA, et al: Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood: A Pediatric Oncology Group Phase II study. Cancer 71:1898-1903, 1993
7. Miser JS, Kinsella TJ, Triche TJ, et al: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987
8. Fidler IJ, Sone S, Fogler WE, et al: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A 78:1680-1684, 1981
9. MacEwen EG, Kurzman ID, Rosenthal RC, et al: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81:935-938, 1989
10. Kleinerman ES, Snyder JS, Jaffe N: Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 9:259-267, 1991
11. Kleinerman ES, Meyers PA, Raymond AK, et al: Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 17:181-193, 1995
12. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004-2011, 2005
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. DeMets DL, Lan KK: Interim analysis: The alpha spending function approach. Stat Med 13:1341-1352, 1994
15. Rosen G, Marcove RC, Caparros B, et al: Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163-2177, 1979
16. Chou AJ, Merola PR, Wexler LH, et al: Treatment of osteosarcoma at first recurrence after contemporary therapy: The Memorial Sloan-Kettering Cancer Center experience. Cancer 104:2214-2221, 2005
17. Hawkins DS, Arndt CA: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98:2447-2456, 2003
18. Kempf-Bielack B, Bielack SS, Jurgens H, et al: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-568, 2005
19. Souhami RL, Craft AW, Van der Eijken JW, et al: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 350:911-917, 1997